ReviewCureus2026
Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an important therapeutic class for the management of type 2 diabetes mellitus (T2DM) and obesity owing to their ability to improve glycemic control, promote weight loss, reduce cardiometabolic parameters, and have the added advantage of a low risk of hypoglycemia due to glucose-independent insulin secretion. Semaglutide, a long-acting GLP-1 RA developed using a semi-recombinant process, has demonstrated significant benefits across metabolic and cardiovascular outcomes. Amid the increasing need for affordable therapies, there has been a rising interest in developing synthetic peptide versions of glucagon-like peptide-1 (GLP-1)-based drugs originally produced using recombinant deoxyribonucleic acid (rDNA) technology. However, the transition from recombinant production to chemical peptide synthesis raises important considerations about regulatory pathways, manufacturing processes, and potential clinical implications. Regulatory approaches for synthetic peptides vary across regions. The European Union and the United States follow distinct frameworks, with India adopting a risk-based regulatory approach that may require extensive quality, safety, and clinical data. Manufacturing processes can influence impurity profiles, stability, and immunogenicity, potentially affecting clinical outcomes. Therefore, the approval of follow-on versions of semaglutide requires a rigorous demonstration of both quality and clinical comparability with the originator, consistent with principles applied to biosimilars. Online databases such as PubMed, Scopus, and Google Scholar were used to source relevant research articles. This narrative review aims to discuss the development of semaglutide, examine global and national regulatory perspectives on synthetic and recombinant peptides, and explore the clinical implications of manufacturing variability. It also highlights the expanding therapeutic potential of semaglutide beyond obesity and T2DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.